Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Deffered Revenue (2016 - 2020)

Ptc Therapeutics has reported Non-Current Deffered Revenue over the past 7 years, most recently at $1.8 million for Q1 2020.

  • Quarterly results put Non-Current Deffered Revenue at $1.8 million for Q1 2020, down 80.03% from a year ago — trailing twelve months through Mar 2020 was $1.8 million (down 80.03% YoY), and the annual figure for FY2019 was $3.4 million, down 64.87%.
  • Non-Current Deffered Revenue for Q1 2020 was $1.8 million at Ptc Therapeutics, down from $3.4 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for PTCT hit a ceiling of $11.2 million in Q3 2018 and a floor of $1.6 million in Q4 2016.
  • Median Non-Current Deffered Revenue over the past 5 years was $7.2 million (2017), compared with a mean of $6.4 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 401.2% in 2017 and later plummeted 80.03% in 2020.
  • Ptc Therapeutics' Non-Current Deffered Revenue stood at $1.6 million in 2016, then surged by 401.2% to $8.0 million in 2017, then grew by 22.23% to $9.7 million in 2018, then tumbled by 64.87% to $3.4 million in 2019, then tumbled by 48.23% to $1.8 million in 2020.
  • The last three reported values for Non-Current Deffered Revenue were $1.8 million (Q1 2020), $3.4 million (Q4 2019), and $5.5 million (Q3 2019) per Business Quant data.